Assessing cardiovascular risk:
resources for you

Want to learn more about advanced cardiovascular testing from Quest Diagnostics? Below are a number of resources covering a variety of topics important to you, from inflammatory markers to LDL-C calculation to advanced lipid testing.

The Martin-Hopkins Calculation for LDL-C

Learn more about lipid testing from Quest that uses the new Martin-Hopkins calculation for LDL-C, offering increased accuracy and convenience.

Cardio IQ® Advanced Cardiovascular Testing

Cardiovascular risk assessment has expanded beyond lipid values to include lipoprotein and apolipoprotein risk factors. Learn more about advanced lipid testing from Quest in this brochure.

Cardio IQ®: managing residual risk with advanced cardiovascular insights

Review key attributes of Quest’s Cardio IQ® reports to find out how the Cardio IQ® solution may help you assess baseline risk, guide personalized therapy, and monitor response to therapy.

Cardio IQ® Ion Mobility

The insights provided by lipid subclasses allow for a customized approach to cardiovascular risk management. Cardio IQ® Ion Mobility fractionation is the latest technological evolution in advanced lipid subclass measurement. Learn more in this brochure.

An early diagnosis can make a lifetime of difference

Today, familial hypercholesterolemia (FH) is generally underdiagnosed and undertreated. This brochure explains how Cardio IQ® genetic testing for FH from Quest may help lead to knowing sooner so cardiovascular care can be optimized.

Focus on earlier identification of heart failure risk

The recently updated ACCF/AHA guidelines for the management of heart failure (HF) recommend BNP or NTproBNP biomarker testing followed by early intervention as an aid for prevention. Learn more about Quest advanced biomarker testing in this brochure.

Biomarker assessments for patients with heart failure

Review this overview of recommendations from the 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure.

Size and density matter: how advanced lipid testing can uncover residual risk

Cardiovascular risk assessment has evolved beyond standard lipid panel values. In this white paper, we discuss how assessing emerging biomarkers may help physicians improve their management of cardiovascular patients, for better health and practice outcomes.

Inflammatory markers in cardiovascular health: a quick overview

In addition to lipids, measuring inflammatory biomarkers in patients being treated for elevated LDL-C may help physicians see the complete picture, uncovering a patient’s hidden risk for cardiac events and enabling them to take the right actions. Learn more in this white paper.

Know a more comprehensive story: the role of injury and inflammation in cardiovascular disease risk

See how lipoprotein risk factors and inflammatory markers may offer you deeper insight into a patient's risk for cardiovascular disease progression in this useful infographic.

Learn more about advanced testing from Quest.

Contact Quest Genomics Client Services to speak with a genetic counselor at 1.866.436.3463
Contact us